Halberd (Halberd) Equity-to-Asset : -77.17 (As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Halberd's Total Stockholders Equity for the quarter that ended in Jul. 2023 was $-0.93 Mil. Halberd's Total Assets for the quarter that ended in Jul. 2023 was $0.01 Mil. Therefore, Halberd's Equity to Asset Ratio for the quarter that ended in Jul. 2023 was -77.17.

The historical rank and industry rank for Halberd's Equity-to-Asset or its related term are showing as below:

HALB' s Equity-to-Asset Range Over the Past 10 Years
Min: -77.17 Med: -60 Max: -42.82
Current: -77.17

During the past 3 years, the highest Equity to Asset Ratio of Halberd was -42.82. The lowest was -77.17. And the median was -60.00.

HALB's Equity-to-Asset is ranked worse than
99.42% of 1561 companies
in the Biotechnology industry
Industry Median: 0.67 vs HALB: -77.17

Halberd Equity-to-Asset Historical Data

The historical data trend for Halberd's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Equity-to-Asset Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Equity-to-Asset

-0.11

-42.82

-77.17

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Equity-to-Asset	-0.11	-42.82	-77.17

Competitive Comparison of Halberd's Equity-to-Asset

For the Biotechnology subindustry, Halberd's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Halberd's Equity-to-Asset falls into.

Halberd Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Halberd's Equity to Asset Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Equity to Asset (A: Jul. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.926	/	0.012
	=	-77.17

Halberd's Equity to Asset Ratio for the quarter that ended in Jul. 2023 is calculated as

Equity to Asset (Q: Jul. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.926	/	0.012
	=	-77.17

Halberd (OTCPK:HALB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Halberd Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Halberd's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236